• Scholar Rock flagged a delay risk for an EMA CHMP opinion on apitegromab’s MAA in spinal muscular atrophy.
• Timing hinges on the FDA’s inspection classification for Catalent Indiana’s fill-finish site following an April 2026 inspection.
• If reclassified, the CHMP opinion is expected later in 2026; otherwise the MAA may shift to a second fill-finish facility.
• U.S. BLA review continues with a Sept. 30, 2026 PDUFA action date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607200800BIZWIRE_USPR_____20260719_BW465114) on July 20, 2026, and is solely responsible for the information contained therein.